newsfilter
← Latest News
GlobeNewswire·

Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID

Initial Study to Evaluate Pharmacokinetics, Biomarkers and Safety of STAT-205 Targeting Preliminary Data 2022 FORT COLLINS, Colo., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma (NASDAQ:STAB), a leading biopharmaceutical company creatin